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Abstract
WAP-8294A is a family of at least 20 cyclic lipodepsipeptides exhibiting potent anti-MRSA 
activity. These compounds differ mainly in the hydroxylated fatty acyl chain; WAP-8294A2, the 
most potent member of the family that reached clinical trials, is based on (R)-3-hydroxy-7-
methyloctanoic acid. It is unclear how the acyl group is incorporated because no acyl-CoA ligase 
(ACL) gene is present in the WAP-8294A gene cluster in Lysobacter enzymogenes OH11. Here, 
we identified seven putative ACL genes in the OH11 genome and showed that the yield of 
WAP-8294A2 was impacted by multiple ACL genes with the ACL6 gene having the most 
significant effect. We then investigated several (R)-3-hydroxy fatty acids and their acyl SNAC (N-
acetylcysteamine) thioesters as substrates for the ACLs. Feeding (R)-3-hydroxy-7-
methyloctanoate-SNAC to the ACL6 gene deletion mutant restored the production of 
WAP-8294A2. Finally, we heterologously expressed the seven ACL genes in E. coli and purified 
six of the proteins. While these enzymes exhibit a varied level of activity in vitro, ACL6 showed 
the highest catalytic efficiency in converting (R)-3-hydroxy-7-methyloctanoic acid to its CoA 
thioester when incubated with coenzyme A and ATP. These results provided both in vivo and in 
vitro evidence to support the fact that ACL6 is the main player for fatty acyl activation and 
incorporation in WAP-8294A2 biosynthesis. The results also suggest that the molecular basis for 
the acyl chain diversity in the WAP-8294A family is the presence of functionally overlapping 
ACLs.
Introduction
The discovery of new anti-infective drugs is a pressing and continual need for human health 
due to the constant emergence of drug resistant pathogens.1,2 Nosocomial infections caused 
by methicillin-resistant Staphylococcus aureus (MRSA) have become an especially serious 
clinical problem. It is imperative to discover and develop new antibiotics. Natural products 
(NPs) are the most significant source of anti-infectives3 and we have been using Lysobacter 
species as a new source for bioactive NP discovery.4–10 WAP-8294A (Fig. 1), a family of 
compounds displaying anti-MRSA activity, are cyclic lipodepsipeptides originally isolated 
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from Lysobacter staphylocidin.11–13 Cyclic depsipeptides belong to a large and diverse 
family of nonribosomally synthesized peptides that have a wide variety of important 
biological activities.14–16 WAP-8294A2 (lotilibicin), the most potent antibacterial of the 
family, exhibit 14-fold greater anti-MRSA activity compared with vancomycin; an IV 
formulation was in phase-I clinical studies in 2010.12,17,18
Although WAP-8294A compounds were first isolated nearly two decades ago, the study of 
their biosynthetic mechanism was reported only in 2011.11,12 Improved understanding of the 
molecular mechanism of biosynthesis could open rational approaches to generate new 
analogs with improved clinical properties. We have identified the WAP biosynthetic gene 
cluster from L. enzymogenes OH11, which includes two large nonribosomal peptide 
synthetase (NRPS) genes. The NRPSs comprise a total of 12 modules that make 45 
functional domains, which are responsible for the assembly of the 12-amino acid core 
structure of WAP-8294A compounds.11
The WAP-8294A family all contains a 3-acyloxy amide linkage derived from a (R)-3-
hydroxy fatty acyl chain; individual family members differ in the length of the chain and the 
presence or absence of a branching methyl group (Fig. 1). The fatty acids must be activated 
before incorporation into the peptide. The mechanism is likely to involve activation of fatty 
acids to their corresponding acyl coenzyme A (CoA) thioesters by a family of acyl CoA 
ligases (ACL). This catalytic process occurs in two steps and involves requisite formation of 
an acyladenylate (acyl-AMP) intermediate.19 Acyl CoA ligases are usually located within 
the biosynthetic cluster associated with formation of the remainder of the natural product. 
For example, the gene clusters for amphi-enterobactin,20 daptomycin16 and calcium-
dependent antibiotic (CDA)21 all host a dedicated ACL and an ACP (acyl carrier protein) for 
the activation and incorporation of the fatty acyl chain. It is therefore interesting that there is 
no ACL gene present in or near the WAP gene cluster,11 a phenomenon previously observed 
with the gene cluster for surfactin.22 In addition, no dedicated ACP is present within the 
WAP cluster. These features suggest that the WAP-8492A biosynthetic pathway likely 
recruits an ACL in trans and that the fatty acids are directly activated as acyl-S-CoA 
thioesters, instead of acyl-S-ACP, for the incorporation into the peptide core.
The aim of this work is to determine the molecular basis for activation and incorporation of 
fatty acyl chains in the biosynthesis of members of the WAP-8294A family, particularly for 
the most eminent member WAP-8294A2. Here we describe both the in vivo and in vitro 
results obtained from the study of seven putative ACLs found in the genome of L. 
enzymogenes OH11. Our study shows that multiple ACLs contribute to WAP-8294A 
biosynthesis and that ACL6 is the most important enzyme in the activation of (R)-3-
hydroxy-7-methyloctanoic acid and incorporation into WAP-8294A2.
Results and discussion
Multiple acyl-CoA ligases contribute to WAP-8294A biosynthesis
We identified seven putative ACL genes in the genome of L. enzymogenes OH11 that are 
associated with secondary metabolism (Fig. S1A). The ACL genes are either associated with 
NRPS-PKS gene clusters, or adjacent to genes related to biosynthesis and regulation of 
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natural products, such as genes encoding lantibiotic-modifying enzyme, enoyl-CoA 
hydratase, or two-component regulatory system. To test if any of the ACLs is involved in 
WAP-8294A biosynthesis, we disrupted each of the 7 ACL genes (Fig. S2 and S3). The 
HPLC and MS analysis showed that the disruption of ACL1, ACL5, and ACL7 had little 
impact on the yield of WAP-8294A2, whereas the disruption of ACL2, ACL3, ACL4, and 
ACL6 significantly reduced the yield (Fig. 2). In particular, the ACL6 mutant produced a 
barely detectable amount of WAP-8294A2. Thus we mainly focused on ACL6 in subsequent 
experiments. The results suggest that multiple ACLs contribute to the fatty acyl chain 
activation and incorporation in WAP-8294A2 biosynthesis, and the ACLs are functionally 
redundant.
Feeding fatty acyl precursor restored WAP-8294A2 production in ACL6 in-frame deletion 
mutants
To eliminate potential polar effects caused by insertion of the conjugal vector in the gene 
disruption mutants, we also generated in-frame deletion mutants for ACL6 gene (Fig. S3). 
WAP-8294A2 production in this mutant strain was monitored by HPLC and MS (Fig. 3). 
Similar to that in the ACL6 disruption mutant, WAP-8294A2 production in the in-frame 
deletion mutant was nearly completely eliminated. We chemically synthesized the N-acetyl 
cysteamine thioester (SNAC) of (R)-3-hydroxy-7-methyloctanoic acid (Fig. 4); details are 
provided in Supplementary Information. This compound was used as the acyl-CoA 
surrogate to be fed to the ACL6 deletion mutant. HPLC analysis clearly showed that 
WAP-8294A2 production was restored in the ACL6 mutant (Fig. 3). This result 
demonstrated that ACL6 is the predominant enzyme responsible for fatty acyl incorporation 
into WAP-8294A2.
Heterologous expression of ACL genes and in vitro assay of the enzyme activity
We cloned the seven putative ACL genes in pET28A and heterologously expressed the 
genes in E. coli. The expressed proteins were purified, except ACL2 which was produced 
mostly as an insoluble protein (Fig. S4). As judged by SDS-PAGE, the observed molecular 
masses of ACL1 through ACL7, including the His6 tag, were consistent with the predicted 
masses (58.7, 58.8, 60.4, 59.8, 61.0, 47.2, 58.6 kDa) calculated from the amino acid 
sequences (Fig. S4).
The enzyme activity of ACLs 1–7 was measured by incubating the enzymes with (R)-3-
hydroxy-7-methyloctanoic acid, ATP, and CoA. A distinct peak in HPLC was detected 
around 9.2 min in the reaction containing ACL6. This peak was collected and analyzed by 
MS, which gave a [M+H]+ of m/z 924.93, consistent with the mass of 3-hydroxy-7-
methyloctanoyl-CoA (calculated mass 923.23) (Fig. 5 and S5). Tandem mass spectrometry 
was used to fragment the analytes into product ions. Both the fatty acyl-CoA precursor ion 
(m/z 924.30) and its product ions (m/z 428.10, 417.20) were detected, while the control 
reaction (w/o enzyme) only gave the product ions of CoA (m/z 480.10 and m/z 261.20). The 
results support the hypothesis that ACL6 catalyzes acyl-CoA formation from the fatty acid 
and CoA. Other ACL also showed some activity, but the product was formed in such minute 
amounts that the peak could only be detected by MS. In addition, we tested (R)-3-
hydroxyoctanoic acid, which corresponds to the fatty acyl portion of WAP-8294A1 (Fig. 1). 
Chen et al. Page 3
RSC Adv. Author manuscript; available in PMC 2016 December 09.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
HPLC and MS data showed a peak around 9 min that gave a [M+H]+ of m/z 911.00 when 
ACL5 was incubated with (R)-3-hydroxyoctanoic acid, CoA and ATP (data not shown). The 
result indicates that ACL5 is able to catalyze the acyl-CoA formation from (R)-3-
hydroxyoctanoic acid and CoA.
To further confirm the specificity of the enzymes, we performed kinetic analysis, using 
EnzChek Pyrophosphate Assay Kit. The inorganic pyrophosphatase in this kit catalyzes 
conversion of PPi into two equivalents of Pi. The Pi is then consumed by the 2-amino-6-
mercapto-7-methyl-purine ribonucleoside (MESG) by purine ribonucleoside phosphorylase 
(PNP) and the product, 2-amino-6-mercapto-7-methyl purine, is detected by an increase in 
absorbance at 360 nm. The EnzChek Pyrophosphate Assay Kit had been used for the 
quantitation of PPi in solution or for the continuous determination of PPi released in 
enzymatic reactions.23–25 To measure the activity, ACL was incubated with free fatty acid, 
ATP, CoA and the coupled reaction system provided by the kit as described above. The 
kinetic parameters were determined by initial velocity experiments using the coupled assay 
(Table S2A and S2B). These data were globally fitted to Michaelis-Menten Equation, 
yielding Km values for (R)-3-hydroxy-7-methyloctanoic acid and (R)-3-hydroxyoctanoic 
acid. The data confirmed that ACL6 favored (R)-3-hydroxy-7-methyloctanoic acid as 
substrate, while ACL5 had a faster rate when (R)-3-hydroxyoctanoic was the substrate. The 
relatively slow reaction rates might explain the very low yield of WAP-8294A in L. 
enzymogenes.11 No steady signal was detected in the enzyme-free or ATP-free control 
reactions, showing that the detected signals resulted from the enzymatic activity of ACLs.
Conclusions
Cyclic lipopeptides are an important group of bioactive natural products; this is exemplified 
by the new antibiotic daptomycin (Cubicin). Although many of the peptides exhibit activity, 
WAP-8294A2 is exceptionally potent against MRSA (ED50 14-fold lower than 
vancomycin). WAP-8294A2 reached the Phase-I clinical studies, but appears to have been 
discontinued from the clinical development.18 The reason for discontinuation has not been 
published, but could indicate undesirable pharmaco-properties. The understanding of 
WAP-8294A biosynthetic mechanism is an essential step toward rational engineering the 
biosynthetic machinery to produce new analogs with improved properties. In WAP-8294A 
biosynthesis, the mechanism by which the 3-hydroxy fatty acyl chain is incorporated into 
the peptide is the least understood step.
To get more insights into the molecular basis for the fatty acyl incorporation and 
WAP-8294A structural diversity, we searched the genome of L. enzymogenes OH11 and 
identified seven putative ACL genes. We disrupted each of the seven ACL genes and found 
that none of the mutants completely lost WAP production. The result supports the notion 
that multiple ACL genes are involved in the acyl incorporation, and the function of the 
ACLs is likely redundant. Among the seven mutants, ACL6 appeared to have the highest 
impact on the yield of WAP-8294A2. To prove this, we generated in-frame deletion mutant 
of ACL6 to eliminate potential polar effects caused by gene disruption. We then chemically 
synthesized the acyl-CoA surrogate, (R)-3-hydroxy-7-methyloctanoyl SNAC. WAP-8294A2 
production in the ACL6 deletion mutant was restored upon feeding the synthetic acyl-CoA 
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surrogate. The result confirms ACL6’s role in WAP-8294A2 biosynthesis; it also suggests 
that ACL6 is required for substrate activation, but not NRPS priming. The results support 
that the WAP-8492A biosynthetic pathway recruits ACL in trans and that the first 
condensation domain in the WAP-8492A NRPS can accept acylS-CoA for the incorporation 
of the fatty acyl chain into the peptide core. Interestingly, a phylogenetic analysis of the 
condensation domains of a group of selected NRPS showed that the first C domain of 
WAP-8492A NRPS (WAP_WAPS1_C1) falls into the same subgroup that includes the first 
C domain of Calcium-Dependent Antibiotics (CDA) and Daptomycin, whose biosynthesis 
uses acyl-ACP as substrate (Fig. S1B).
In the in vitro studies, we were able to express six of the seven putative ACL genes in E. coli 
and to purify the proteins for enzyme activity assay and kinetic studies. The enzyme activity 
was demonstrated by the conversion of the chemically synthesized (R)-3-hydroxy fatty acids 
to the corresponding CoA thioesters, when the purified ACLs were incubated with the 
substrate, CoA and ATP. The kinetic data revealed that (R)-3-hydroxy-7-methyloctanoic 
acid is the preferred substrate for ACL6. These observations are consistent with the results 
obtained from ACL mutants and in vivo feeding experiment. Together, the results support 
that ACL6 is the most important enzyme for fatty acyl incorporation into WAP-8294A2, and 
ACL5 may be an important contributor for the fatty acyl incorporation into WAP-8294A1. 
Based on the results presented in this study, we propose a mechanism for the initiation of the 
biosynthesis of WAPs, as shown in Fig. 6.
Experimental procedures
Chemicals, bacterial strains, plasmids, and general procedures for DNA manipulation
Chemicals used in this study were purchased from Fisher Scientific, Sigma, and Acros. 
Oligonucleotide primers for PCR were synthesized by Eurofins MWG Operon. Plasmid 
preparation and DNA extraction were carried out with Qiagen kits (Valencia, CA), and all 
other DNA manipulations were carried out according to standard methods. Ni-NTA agarose 
was purchased from Qiagen (Valencia, CA). Escherichia coli strain XL Blue was used as 
the host for general plasmid DNA propagation, and the cloning vector was pANT841. 
Vector pET28a was used for protein expression in E. coli BL21 (DE3). E. coli S17-1 was 
used as the conjugal strain to transfer DNA into Lysobacter. L. enzymogenes and other 
bacterial strains were grown in Luria-Bertani (LB) broth medium, 1/10-strength tryptic soy 
broth (1/10 TSB, Sigma) or NYGB/A medium. EnzChek Pyrophosphate Assay Kit was 
purchased from Sigma.
Generation of gene disruption mutants
To construct plasmids for gene disruption, an internal fragment was amplified from each of 
the open reading frames (ORFs) using the primer pairs described in Supporting Information 
(Table S1). Genomic DNA from the wild type L. enzymogenes OH11 served as the PCR 
template. The homologous regions of these ACLs were amplified by PCR and introduced 
into the conjugation vector pJQ200SK to produce pJQ200SK-ACLs. Each of the pJQ200SK 
constructs was transformed into E. coli S17-1, which was mated with L. enzymogenes OH11 
for conjugal transfer of the vectors. The positive colonies grown on LB plates containing 
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gentamicin (20 μg/mL) were picked up and inoculated into liquid cultures containing 
gentamicin. Genomic DNA was prepared from each of the cultures, and diagnostic PCR was 
performed to identify mutants that resulted from a homologous recombination. To screen the 
ACL gene disruption mutants, PCR was performed using the diagnostic primers listed in 
Table S1, which would amplify correct fragments when mutants resulted from a 
homologous recombination, but not from the wild type or mutants resulted from a random 
insertion of the construct (Fig. S2 and S3).
Production and analysis of metabolites in mutant strains
L. enzymogenes OH11 and its mutants were grown in 1/10 TSB for 1 day, and an aliquot of 
200 l was spread on a solid NYGA plate (bacteriological peptone, 5 g/L; yeast extract, 3 
g/L; glycerol, 20 g/L, and agar 15 g/L). The plates were incubated at 28 °C for 2 days. To 
extract the metabolites, the solid media were collected and extracted with methanol. The 
methanol extract was dried with a rotavapor (Buchi, Rotavapor R-200) to afford the crude 
extract, which was dissolved in 2 mL methanol containing 0.05% TFA. A 20 μl aliquot of 
each of the extracts was analyzed by HPLC (1220 Infinity LC, Agilent Technologies) using 
a reversed-phase column (Cosmosil 5C18-AR-II, 4.6 ID × 250 mm). Water/0.01 M TFA 
(solvent A) and acetonitrile/methanol = 1:1 (solvent B) were used as the mobile phases with 
a flow rate of 1.0 mL/min. The HPLC program was as follows: 57% B in A in the first 5 
min, 57–100% B in 5–32 min, 100% B in 32–40 min, back to 57% B at 41 min, and 
maintained to 48 min. The metabolites were detected at 280 nm on a UV detector. LCQ-MS 
was used to verify the mass of the peak of WAP-8294A2 and analogs.
Generation of gene deletion mutants
To construct the ACL6 in-frame deletion vector, primer extension PCR reactions were 
performed to generate a 705-bp fragment from both the upstream and downstream regions of 
ACL6 gene. Homologous recombination at both regions would delete the entire ACL6 gene 
without interference with other genes. The primers used for these experiments are listed in 
the Table S1. The PCR amplified fragment was then cloned into the conjugal vector 
pJQ200SK as an XhoI/BamHI fragment to produce pJQ200SK-ACL-6. To conjugally 
transfer pJQ200SK-ACL-6 into L. enzymogenes OH11, the procedure was identical to the 
previously described.11 The correct single crossover mutant was selected by diagnostic PCR 
(Fig. S3). Individual colonies of confirmed single crossover mutants were subjected to liquid 
cultures containing 5% (W/V) sucrose to select for the loss of the vector through a second 
homologous recombination. The single crossover mutants were grown in 1/10 TSB medium 
for 14 hours. Then the individual cultures were re-inoculated into 1/10 TSB (with 1:100 
ratio) containing 5% sucrose and 25 μg/mL kanamycin medium. Aliquots (50 μl) were 
removed every 3 hours from this liquid culture and spread onto 1/10 TSA plates (5% 
sucrose, 25 μg/mL kanamycin). Single colonies were picked up from the plates and allowed 
to grow in 1/10 TSB (5% sucrose, 25 μg/mL kanamycin) liquid medium for another 2–5 
days. To confirm the double crossover mutant, another diagnostic PCR was performed using 
genomic DNA extracted from the single colonies as template (Fig. S3).
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Synthesis of (R)-3-hydroxy fatty acids and (R)-3-hydroxy fatty acyl SNAC
To generate the initial carbon backbone, we generated the dianion of methyl acetoacetate 
with LDA then subsequent alkylation with an appropriate bromoalkane to create the target 
carbon skeleton in roughly 20c50% yields (1a–b) (Fig. 4).26 A subsequent asymmetric 
reduction of the β-keto ester with borane dimethyl sulfide complex in the presence of a 
commercial oxazaborolidine catalyst provides the beta hydroxy esters 2a–b in 20–40% yield 
with a 90–92% enantiomeric excess of the R isomer.27 Hydrolysis of the methyl esters to the 
carboxylic acids can be accomplished in almost quantitative yield (3a–b) in the presence of 
LiOH. Selective formation of thioesters 4a–b in the presence of the free alcohol is 
accomplished in 70–80% yield through carbodiimide-mediated coupling with SNAC in the 
presence of stoichometric DCC and catalytic DMAP (see Supporting Information for 
details).
Feeding of ACL6 deletion mutant with 3-hydroxy-7-methyloctanoyl SNAC
ACL6 in-frame deletion mutant was grown in 1/10 TSB for 1 day, and an aliquot of 1 mL 
was inoculated into two 1 liter NYGB liquid cultures. The culture was fed with the fatty 
acyl-SNAC dissolved in DMSO under pulse feeding on 2 following days (0.12 mmol/L and 
0.06 mmol/L) following a reported procedure.28 Metabolites were extracted from the 
supernatant with ethyl acetate: methanol: acetic acid = 80: 15: 5. The organic phase was 
dried under reduced pressure (rotary evaporator) to afford the crude extract. The extract was 
dissolved in 2 mL methanol containing 0.05% TFA. A 20 μl aliquot of each of the extracts 
was analyzed by HPLC as described above.
Expression of seven ACL genes and purification of the enzymes
To construct expression vectors, the coding region of each of the seven ACL genes was 
amplified by PCR using genomic DNA of L. enzymogenes OH11 as template. The primers 
are listed in Table S1. Each of the PCR fragments was digested and cloned into pANT841. 
The cloned gene in each of the constructs was sequenced, and the result showed that all the 
ACL sequences were correct. The ACL genes were released from pANT841 and cloned into 
the expression vector pET28a. The pET28a constructs were introduced into E. coli 
BL21(DE3). Individual colonies were inoculated in 3 mL of liquid LB medium containing 
kanamycin (50 μg/mL) and incubated in a shaker (250 rpm) at 37 °C overnight. The culture 
was then added to 50 mL fresh LB medium and incubated in a shaker (250 rpm) at 37 °C 
until the cell density (OD600) reached 0.6. To induce the expression of the ACL genes, IPTG 
(0.1 mM) was added to the cultures, and the cells were allowed to grow at the same 
conditions for another 3 h. To extract proteins, the cells were harvested and resuspended in 2 
mL of Tris-HCl buffer (250 mM NaCl, 100 mM LiCl, 50 mM Tris, pH 7.8). The cell 
suspension was treated with lysozyme (1 mg/mL) and sonicated five times (3-second 
sonication with 2-second pause) on ice. The soluble fraction of protein extracts was loaded 
onto a Ni-NTA column, which was previously calibrated with Tris buffer containing 10 mM 
imidazole. The column was washed three times with Tris buffer containing 20 mM 
imidazole, and the His6-tagged protein was eluted twice with 200 μl of Tris buffer 
containing 250 mM imidazole. The eluted proteins were checked by SDS-PAGE (Fig. S4). 
Chen et al. Page 7
RSC Adv. Author manuscript; available in PMC 2016 December 09.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
The fractions containing pure ACLs were collected and dialyzed against Tris buffer 
containing 15 % glycerol.
In vitro assay of acyl-CoA ligase activity
Enzymatic reactions to generate fatty acyl-CoA were set up using the following conditions: 
10 μM ACL, 0.2 mM CoA, 10 mM ATP, 20 μM fatty acid in DMSO, 5 mM MgCl2, 0.2% 
(w/v) Triton, 200 μM DTT, and 100 mM Tris-HCl pH 7.8. All reactions were incubated at 
30 °C overnight. Samples were analyzed by HPLC (1220 Infinity LC, Agilent Technologies) 
using a reversed-phase column (Phenomenex, 4.6 ID × 150 mm). Water containing 25 mM 
ammonium acetate and 0.5% acetic acid (solvent A) and acetonitrile containing 0.5% acetic 
acid (solvent B) were used as the mobile phases with a flow rate of 1.0 mL/min. The HPLC 
program was as follows: 10% B in A in the first 3 min, 10–90% B in 3–15 min, 90% B in 
15–25 min, back to 10% B at 26 min, and maintained to 30 min.29 The metabolites were 
detected at 260 nm on a UV detector. MS (Finnigan mat, LCQ) was used to verify the mass 
of the reaction products. LC-MS/MS was used to further confirm the product. An Agilent 
LC-1200 (Santa Clara, CA) was connected to a 2.1 × 100 mm Symmetry ODS column from 
Waters (Milford, MA) and a Triple Quadrupole Mass Spectrometer model 4000 QTrap from 
ABSciex (Framingham, MA) operating in either single quadrupole (Q1), enhanced mass 
spectrum (EMS), MS/MS or multiple reaction monitoring (MRM) modes. The samples were 
injected onto the column and eluted with 98% mobile phase A (0.1% formic acid in water, 
J.T. Baker) to 60% B (0.1% formic acid in acetonitrile, Acros Organics) over 15 minutes, 
followed by 5 minutes of 98% B and 5 min of 98 % A, all at a flow rate of 0.25 mL/min.
Kinetic analysis of acyl-CoA ligase activity
The EnzChek Pyrophosphate Assay Kit (Molecular Probes™) was used to measure the 
activities of ACLs. A standard curve (y = 0.0156x + 0.0004, R2 = 0.99603) for the 
pyrophosphate assay was generated using pyrophosphate standard as a source of PPi. To 
measure the activity of ACLs, the following reagents were combined in 0.1 mL reaction 
volumes: 0.4 mM ATP, 0.4 mM CoA, 0.4 mM free fatty acids in DMSO, 0.2 mM 2-
amino-6-mercapto-7-methyl-purine ribonucleoside (MESG), 1 U purine nucleoside 
phosphorylase (PNP), 0.01 U pyrophosphatase, and various ACLs with final concentration 
of 15 μM. After incubating at 22 °C for 30 minutes, the absorbance at 360 nm was measured 
and corrected for background absorbance. The substrates tested were chemically synthesized 
(R)-3-hydroxy-7-methyloctanoic acid (corresponding to the fatty acyl chain in WAP 8294-
A2) and (R)-3-hydroxyloctanoic acid (corresponding to the fatty acyl chain in WAP 8294-
A1). The kinetic parameters of ACLs were determined by initial velocity experiments using 
the coupled assay. These data were globally fitted to Michaelis-Menten Equation, yielding 
Km values for the substrates.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
Structure of the two main members of the WAP-8294A family.
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Fig. 2. 
HPLC analysis of metabolites from various strains of Lysobacter enzymogenes OH11. A: 
OH11 wild type; B-H: disruption mutants of ACL1 through ACL7, respectively; I: 
WAP-8294A2 standard. The detection wavelength was 280 nm.
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Fig. 3. 
HPLC analysis of metabolites in strains of Lysobacter enzymogenes OH11. A: ACL6 in-
frame deletion mutant; B: The ACL6 mutant supplemented with (R)-3-hydroxy-7-
methyloctanoic acyl-SNAC; C: WAP-8294A2 standard.
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Fig. 4. 
Chemical synthesis of (R)-3-hydroxy fatty acids and 3-hydroxy fatty acyl-SNAC (acyl 
thioester of N-acetyl cysteamine).
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Fig. 5. 
HPLC and MS analysis of in vitro reaction products of ACL6 incubated with 3-hydroxy-7-
methyloctanoic acid, ATP, and CoA. The ESI-MS signals were measured in positive single 
ion mode. A: HPLC of control reaction (without enzyme); B: HPLC of ACL6 reaction; C: 
ESI-MS analysis of the ACL6 reaction product, the distinct peak in HPLC as indicated by a 
star. The calculated mass of 3-hydroxy-7-methyloctanoyl-CoA is 923.23 (see Fig. S5).
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Fig. 6. 
Proposed mechanism for fatty acid incorporation in WAP-8294A2 biosynthesis. The fatty 
acid, (R)-3-hydroxy-7-methyloctanoic acid, is activated by ACL6, and the resultant acyl-
CoA is then recognized by the condensation (C) domain of the NRPS, which catalyzes the 
amide bond formation between the PCP-bound L-serine and the fatty acyl-CoA.
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